

Results for the first half of the 2022/2023 financial year

Adjustment in a Still Deteriorating Environment.

CONSOLIDATED DATA AS OF THE END OF DECEMBER (in millions of euros)	2021/22	2022/23	Variance
Turnover	401.7	364.6	-9.2%
Operating EBITDA	13.8	8.0	-41.9%
EBITDA (including IFRS 16)	22.2	17.1	
Current operating profit	10.0	(1.6)	-115.7%
Non-current operating items	(0.1)	3.2	
Impairment of assets	0.0	(3.0)	
Financial result	0.6	(0.5)	
Income tax	(1.3)	(1.0)	
Net profit	9.3	(2.9)	-131.5%
Capex	16.5	6.6	
Net financial surplus	17.7	(67.9)	

ACTIVITY

Damartex concludes the first half of the 2022/2023 financial year with a turnover of \notin 364.6 Mn, down against last year (-9.2% at actual exchange rates).

The Fashion division's sales amounted to \leq 284.9 Mn for the first half of the year, down -6.6% at actual exchange rates, despite the good performance of Damart's stores and the Xandres brand.

The **Home & Lifestyle** division posted sales of \in 58.1 Mn, down -27.6% at actual exchange rates, still affected by the contraction in consumption in the home equipment sector, particularly in the German and UK markets.

The **Healthcare** division continued to grow, posting a significant increase in revenue of +29.8% at actual exchange rates, reaching



160 Boulevard de Fourmies - F 59100 Roubaix Tel: +33 (0)3 20 99 44 00 - Fax: +33 (0)3 20 11 45 24 www.damartex.com

DAMARTEX



€ 21.6 Mn, driven in particular by the very good performance of Santéol.

RESULTS

The Group's operating EBITDA is \in 8 Mn compared with \in 13.8 Mn last year, mainly due to the decline in business over the period. In an uncertain environment, marked by high inflation and a contraction in demand, a proactive adjustment of the business to market realities enabled margin stability and cost optimization, while maintaining transformation investments.

Operating EBITDA is € +12.6 Mn for the Fashion division, € -6.9 Mn for Home & Lifestyle division, and € +2.3 Mn for the Healthcare division.

Damartex closes this half-year with a **net result of € -2.9 Mn** against € 9.3 Mn for the 1st half-year of 2021/2022.

FINANCIAL SITUATION

The net financial position was \in **-67.9 Mn** as of the end of December 2022 (compared with \in -48.0 Mn at the end of June 2022), reflecting the Group's continued investment, in particular the acquisition of Icelus Médical, and the increase in working capital requirements.

The working capital requirement amounted to \leq 40.6 Mn at the end of December 2022.

OUTLOOK

Damartex believes that the robust pricing power of its brands will remain an asset for the coming months. The Group continues the agile adjustment of its activities, in a context that requires adaptability and caution. In line with the market, the Group is also pursuing its transformation plan: "*Transform To Accelerate TTA 2.0*".

PROFILE

The Damartex Group, one of the main European retailers for seniors, ambitions to become the European leader in the silver economy. It boasts three divisions: - Fashion: Damart, Afibel, Xandres

 Home & Lifestyle: 3 Pagen, Vitrine Magique, Coopers of Stortford
Healthcare: Sedagyl, Santéol, MSanté, Medical Santé
The Group operates mainly in Europe, including in France, Great Britain, Belgium and Germany.
www.damartex.com

CONTACTS

Damartex: Claire Bonnet Tel: +33 (0)3 20 11 47 28 cbonnet@damartex.com

Shan:

Alexandre Daudin Tel: +33 (0)6 34 92 46 15 *alexandre.daudin@shan.fr* Aliénor Kuentz Tel: +33 (0)6 28 81 30 83 *alienor.kuentz@shan.fr*

CALENDAR

- Financial Information Meeting 1st half-year 2022/2023 : 8 March 2023
- Publication of turnover for third quarter 2022/2023: 20 April 2023



DAMARTEX

Société anonyme à Directoire et Conseil de Surveillance Capital: € 57,991,500 RCS Lille Métropole 441 378 312 - VAT No.: FR 73 441 378 312